Zydus Lifesciences receives EIR for its API manufacturing facility at Ambernath

Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra.

This facility underwent an inspection from 10 to 14 February 2025, and had ended with NIL observations. The EIR report has classified it as No Action Indicated (NAI).

Powered by Capital Market - Live News